Lee et al., 2007 - Google Patents
Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at μ and δ opioid receptorsLee et al., 2007
View PDF- Document ID
- 8607376572089538174
- Author
- Lee Y
- Nyberg J
- Moye S
- Agnes R
- Davis P
- Ma S
- Lai J
- Porreca F
- Vardanyan R
- Hruby V
- Publication year
- Publication venue
- Bioorganic & medicinal chemistry letters
External Links
Snippet
New 4-anilidopiperidine analogues in which the phenethyl group of fentanyl was replaced by several aromatic ring-contained amino acids (or acids) were synthesized to study the biological effect of the substituents on μ and δ opioid receptor interactions. These analogues …
- 102000037275 μ-opioid receptors 0 title abstract description 25
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mabonga et al. | Peptidomimetics: a synthetic tool for inhibiting protein–protein interactions in cancer | |
| US7807678B2 (en) | Peptidomimetics of biologically active metallopeptides | |
| Cai et al. | Biological and conformational study of β‐substituted prolines in MT‐II template: steric effects leading to human MC5 receptor selectivity | |
| Becker et al. | Ligands for κ-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library | |
| US20100311648A1 (en) | Melanocortin receptor-specific peptides | |
| AU2002331064A1 (en) | Peptidomimetics of biologically active metallopeptides | |
| Lee et al. | Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at μ and δ opioid receptors | |
| Mollica et al. | New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4, 4′ positions and non-hydrazine linkers | |
| Fung et al. | Design of cyclic and other templates for potent and selective peptide α-MSH analogues | |
| Anand et al. | Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models | |
| Lee et al. | Development of novel enkephalin analogues that have enhanced opioid activities at both μ and δ opioid receptors | |
| Ballet et al. | Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1, 2, 4, 5-tetrahydro-2-benzazepin-3-one (Aba) scaffold | |
| Gentilucci et al. | Investigation of the interaction between the atypical agonist c [YpwFG] and MOR | |
| Sagan et al. | Structural and biological effects of a β2‐or β3‐amino acid insertion in a peptide: Application to molecular recognition of substance P by the neurokinin‐1 receptor | |
| Salvadori et al. | A new opioid designed multiple ligand derived from the μ opioid agonist endomorphin-2 and the δ opioid antagonist pharmacophore Dmt-Tic | |
| Strack et al. | A blocking group scan using a spherical organometallic complex identifies an unprecedented binding mode with potent activity in vitro and in vivo for the opioid peptide dermorphin | |
| McFadyen et al. | Modifications of the cyclic mu receptor selective tetrapeptide Tyr‐c [d‐Cys‐Phe‐d‐Pen] NH2 (Et): effects on opioid receptor binding and activation | |
| Hruby et al. | Approaches to the rational design of selective melanocortin receptor antagonists | |
| Weißhoff et al. | Mimicry of βII′‐turns of proteins in cyclic pentapeptides with one and without d‐amino acids | |
| Li et al. | Potent Dmt-Tic pharmacophoric δ-and μ-opioid receptor antagonists | |
| Lazarus et al. | Engineering endomorphin drugs: state of the art | |
| Bańkowski et al. | N‐terminal guanidinylation of the cyclic 1, 4‐ureido‐deltorphin analogues: the synthesis, receptor binding studies, and resistance to proteolytic digestion | |
| Piekielna et al. | Redoubling the ring size of an endomorphin‐2 analog transforms a centrally acting mu‐opioid receptor agonist into a pure peripheral analgesic | |
| Weltrowska et al. | Cyclic enkephalin analogs containing various para‐substituted phenylalanine derivatives in place of Tyr1 are potent opioid agonists | |
| Vandormael et al. | Asymmetric Synthesis and Conformational Analysis by NMR Spectroscopy and MD of Aba‐and α‐MeAba‐Containing Dermorphin Analogues |